DCIS patients who get invasive breast cancer have higher mortality

	Tweet

Women with ductal carcinoma in situ—DCIS—who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.

Retrospective studies of women with DCIS have compared breast conserving surgery (lumpectomy) to mastectomy and found that survival rates are similar. However, women who have lumpectomy alone, without further treatment, are at higher risk of developing invasive breast cancer in the same breast. Whether women who develop invasive breast tumors after DCIS are also at higher risk of dying of breast cancer has not been clear.

To explore this question as well as the long-term effects of treatments aimed at avoiding invasive recurrence after lumpectomy, Irene Wapnir, M.D., of Stanford University School of Medicine, and James Dignam, PhD of University of Chicago looked at the long-term outcomes of patients with localized DCIS who took part in two large randomized trials, both carried out by the National Surgical Adjuvant Breast and Bowel Project (NSABP). The B-17 trial compared lumpectomy alone to lumpectomy plus radiation therapy in women with DCIS. The B-24 trial compared lumpectomy plus radiation in combination with either tamoxifen or placebo.

Wapnir and colleagues analyzed data on outcomes in both trials after 15 years, including overall and breast cancer-specific survival and survival after development of invasive breast cancer in the same, or ipsilateral, breast.

They found that the development of invasive ipsilateral breast cancer was associated with death rates that were statistically significantly higher than those in women who did not develop an invasive ipsilateral breast cancer. Recurrence of DCIS was not associated with higher mortality. Radiation treatment after lumpectomy reduced the risk of ipsilateral invasive breast cancer compared to lumpectomy alone, and treatment with radiation and tamoxifen reduced the risk compared to radiation only. The reductions in risk were statistically significant.

Among all patients in the trials, the 15-year cumulative incidence of death from breast cancer was 4.7% or less for all treatment groups. Some of these events could be attributed to new invasive contralateral breast cancers.

The authors conclude that, regardless of treatment, women with DCIS have an excellent overall prognosis “despite persistent risks of breast cancer in the same or contralateral breast.” They note that three other NSABP trials now in progress will provide more information on other treatment options following lumpectomy.

###

Contact: Irene Wapnir, 650-721-5705;

###

Contact: Caroline McNeil

301-841-1286
Journal of the National Cancer Institute

RELATED STORIES:
New breast cancer screening guidelines released   Breast cancer survivors face other cancer risks   New national poll: 89 percent of women said mammograms vital to their health   Does mammogram row signal time for policy shift?   Breast cancer risk tied to grandmother’s diet   Study Finds Diet and Alcohol Alter Epigenetics of Breast Cancer and Could Predict Severity of Diseas   Radiotherapy boost helps early breast cancer   Tumor-free breast tissue can have precancerous changes   Persistent pain common for many women 2 to 3 years after breast cancer treatment   Targeted breast ultrasound can reduce biopsies for women under 40   Concerns raised about surgeons performing occasional breast cancer operations   MRI may cause more harm than good in newly diagnosed early breast cancer   Breast cancer outcome similar in women and men   Moderate Red Wine Drinking May Help Cut Women’s Breast Cancer Risk   How women can improve their quality of life after breast cancer treatment   New Drug Cocktail Extends Lives of Patients with Advanced Breast Cancer   Popular new breast cancer treatment lacks data   Weight Gain/Risk of Breast Cancer in Postmenopausal Women   Soy isoflavones may modify risk of breast cancer   New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks   Biopsy of Recurrent Breast Cancer Can Alter Treatment   Breast cancer treatment knowledge lacking

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]